ClinicalTrials.gg
CompletedNCT02968719Updated Aug 1, 2018

A Phase 1, Corplex™ Donepezil Transdermal System Compared to Oral Aricept®

A Phase 1 interventional study of Donepezil TDS Version A and Donepezil TDS Version B in Alzheimer Disease, sponsored by Corium, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-08-01.

Sponsored by Corium, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
107
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies testing donepezil in Alzheimer Disease — 2 open to participants now, 2 under way, 1 of them phase 3. Donepezil · Alzheimer Disease.

Enrollment
24th of 58
107 · median 79
Started
2016
with 3 others
Phase 1
20 of 60
1 open now
Registered
48th of 60
by date
Lead sponsor
4 of 60
Corium, Inc.

Among the 60 studies testing donepezil in Alzheimer Disease, this one is the 24th largest by enrollment of the 58 interventional ones that give a count, is one of 4 that started in 2016, is one of 20 in phase 1, and was the 48th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

2 of the 60 studies testing donepezil in Alzheimer Disease are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About donepezil

Donepezil: first FDA approval 1996 (ARICEPT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing donepezil in Alzheimer Disease, or all of them as a file.
02

Study summary

A Phase 1, Randomized, Open-Label, 3-Way Crossover, Pilot, Pharmacokinetic Study to Evaluate the Steady State Pharmacokinetics of a Once-Weekly Application of Corplex Donepezil Transdermal Delivery System (TDS) Compared to Daily Oral Administration of Aricept in Healthy Adult Subjects

Read the detailed description

Part A:

60 male and female subjects will be enrolled Subjects will receive 2 versions of once-weekly Corplex Donepezil TDS and QD oral Aricept; each administered for 35 days in 3 different treatment periods.

For each treatment period; Subjects will receive a lead-in dose of approximately 5 mg donepezil/day for 7 days before commencing a dose of 10 mg donepezil/day for 28 days. Blood samples for donepezil PK and red blood cell (RBC) AChEI (as a potential pharmacodynamic [PD] marker) will be collected pre-dose through Week 8.

Adhesion and skin irritation will be monitored throughout TDS Treatments. A washout period of at least 21 days between the last study drug administration (oral administration or removal of TDS, as appropriate) in each treatment period and the first application of TDS or oral drug administration, as appropriate, in the following treatment period.

Safety will be monitored throughout the study by adverse event reporting, repeated clinical and laboratory evaluations

Part B:

Up to 47 subjects male and/or female will be enrolled This is an open-label, randomized, 2-way crossover sub-study. Eligible subjects will be randomized to 1 of 2 treatment sequences prior to the first TDS application.

Subjects will receive 2 different once-weekly Corplex Donepezil TDS treatments (Treatments D and E), each administered for 1 week, in 2 different treatment periods (Treatment Period 1 and Treatment Period 2).

In each treatment period, subjects will receive a target dose of 5 mg donepezil/day for 7 days. There will be a washout period of 35 days between removal of the first TDS in Treatment Period 1 and application of the second TDS in Treatment Period 2.

Blood samples for donepezil PK will be collected pre-dose and through to Week 6 of each treatment period.

Safety will be monitored throughout the sub-study by repeated clinical, skin irritation and laboratory evaluations.

03

Conditions studied

  • Alzheimer Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Healthy, adult, Caucasian, male or female ≥18 years of age at screening
  • ≥ 18.0 and ≤ 32.0 kg/m2 at screening
  • Medically healthy with no medical history, physical examination, laboratory profiles, vital signs or (ECGs), as deemed by the Investigator.
  • Have a Fitzpatrick skin type of I, II or III or have skin colorimeter scores equivalent to the allowed Fitzpatrick skin type.

Key Exclusion Criteria:

  • History or presence of or idiosyncratic reaction to the study drugs or related compounds (including piperidine derivatives and other cholinesterase inhibitors)
  • Has intolerance to venipuncture and/or inability to comply with the extensive blood sampling required for this study or does not have suitable veins in both arms
  • Potential for occupational exposure to anticholinesterase agents.
  • Female subjects with a positive pregnancy test or lactating
  • Positive urine drug or alcohol results
  • Estimated in non-elderly subjects \<80 mL/min at screening and in elderly subjects (i.e., ≥55 years of age) \<60 mL/min at screening
  • value of less than 11.5 g/dl for females, 13.0 g/dl for males at screening and first check-in
  • Any of the following drugs for 28 days prior to the first dose of study drug in Treatment Period 1 and throughout the study:

    • significant inducers of cytochrome P450 (CYP) enzymes and/or P-glycoprotein
    • anti-inflammatory drugs or cyclooxygenase 2 (COX-2) analgesic
    • beta-blockers;
    • anti-fungal medications;
    • anti-histamines;
    • cholinergics and anti-cholinergics;
    • oral ;
    • Prolia;
    • Adjuvant analgesics
  • Muscle relaxants, anti-Parkinsonian or neuroleptic medications prior to the first dose of study drug
  • History or presence of excessive hairy skin on application sites as deemed by the Investigator to potentially interfere with drug absorption
  • History or presence of significant skin damage, diffuse skin diseases, scars, tattoos on the application sites or other skin disturbances as deemed by the Investigator to potentially interfere with drug absorption or irritation assessments
  • Use of donepezil hydrochloride or related drugs within 60 days prior to the first study drug administration
  • Participation in another clinical study within 60 days prior to the first study drug administration
  • Clinically significant depression symptoms or suicidal ideation or behavior as determined by the investigator:
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
107 participants (actual)

Study arms

  • Experimental
    Donepezil TDS Version A

    Lead-in of 5 mg/day donepezil of target dose (1 x Corplex 5 mg donepezil transdermal delivery system; 7 days) followed by; Target dose of 10 mg/day donepezil (Treatment A); Corplex 10 mg donepezil transdermal delivery system. 1x patch will be worn for 7 days. A total of 4 TDS patches will be applied for 4 consecutive 7 day periods.

    Drug: Donepezil TDS Version B · Drug: Aricept

  • Experimental
    Donepezil TDS Version B

    Lead-in of 5 mg/day donepezil of target dose (1 x Corplex 5 mg donepezil transdermal delivery system; 7 days) followed by; Target dose of 10 mg/day donepezil (Treatment B); Corplex 10 mg donepezil delivery transdermal system. 1x patch will be worn for 7 days. A total of 4 TDS patches will be applied for 4 consecutive 7 day periods.

    Drug: Donepezil TDS Version A · Drug: Aricept

  • Active comparator
    10 mg Aricept

    5 mg/day oral Aricept, once daily for 7 days followed by; 10 mg/day Aricept once daily for 28 days

    Drug: Donepezil TDS Version A · Drug: Donepezil TDS Version B

  • Experimental
    Donepezil TDS Version D

    Target dose of 5 mg/day donepezil (Treatment D) Corplex 5 mg Donepezil TDS applied for a duration of 1 week.

    Drug: Donepezil TDS Version D · Drug: Donepezil TDS Version E

  • Experimental
    Donepezil TDS Version E

    Target dose of 5 mg/day donepezil (Treatment E) Corplex 5 mg Donepezil TDS applied for a duration of 1 week

    Drug: Donepezil TDS Version D · Drug: Donepezil TDS Version E

Interventions

  • DrugDonepezil TDS Version A

    Donepezil Hydrochloride Transdermal Delivery System (5mg and 10 mg Version B)

  • DrugDonepezil TDS Version B

    Donepezil Hydrochloride Transdermal Delivery System (5 mg and 10 mg Version B)

  • Aricept (5 mg and 10 mg) Donepezil Hydrochloride

    Also known as: Aricept Tablet

  • DrugDonepezil TDS Version D

    Donepezil Hydrochloride Transdermal Delivery System (5 mg Version D)

  • DrugDonepezil TDS Version E

    Donepezil Hydrochloride Transdermal Delivery System (5 mg Version E)

06

What researchers measure

Primary outcomes

  1. Steady-state PK

    To evaluate the steady-state PK of donepezil following once weekly Corplex Donepezil TDS application compared to once-daily (QD) oral administration of Aricept. Aricept PK sampling time points; Day 1 (hr0,1,2,3,4,6,8,12); Day 2,8,15,22,29 (hr0); Day 35(hr0,1,2,3,4,6,8,12); Day 36-37,40,43,46,49,53 (hr0)

    Time frame: TDS PK sampling time-points: Predose; Day 1 (hr0); Post-dose; Day 1 (hr2,6,12); Day 2-15,22 (hr0); Day 29 (hr0,3,6,12); Day 30-35 (hr0,12) Day 36 (hr0, 2,6,12); Day 37-38,41,44,47,50,54 (hr0);

  2. PK (Part B)

    To compare the PK of 2 once-weekly Corplex Donepezil TDS treatments (target dose 5 mg donepezil/day)

    Time frame: TDS PK sampling time-points: Predose; Day 1 (hr0); Post-dose; Day 1 (hr2,6,12); Day 2-8 (hr0,12); Day 9,10,11,13,16,19,22,26,30,36 (hr0)

Secondary outcomes

  1. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 (Part A and B)

    General Safety (AE and SAE as reported by subject following guidance CTCAE v4.0)

    Time frame: Daily during 36-day confinement period and 7 visits over the 21 day wash-out period.

  2. PI assessment of local skin irritation response to TDS (Part A and B)

    To evaluate the safety and tolerability (including local skin irritation) of once-weekly Corplex Donepezil TDS. Skin irritation assessed using 8 pt categorical scale based on former FDA.gov/ohrms/dockets/98fr/990236GD.pdf. The Skin Irritation scale is: no irritation; minimal erythema/barely perceptible; definite erythema readily visible, minimal edema or minimal papular response; erythema and papules; definite edema; erythema, edema and papules; vesicular eruption; strong reaction spreading beyond application site.

    Time frame: Part A: Daily during 36-day confinement period and 7 visits over the 21 day wash-out period. Part B:Daily during 10-day confinement period and 8 visits over the 28-35 day wash-out period.

  3. PI assessment of TDS Adhesion per FDA UCM504157

    To evaluate the adhesion of once-weekly Corplex Donepezil TDS. Adhesion is based on the adhered area (%) of the patch according to FDA.gov/downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/UCM504157.pdf. Specifically: ≥ 90% adhered (essentially no lift off skin); ≥ 75% to \<90% adhered (some edges only lifting off skin); ≥ 50% to \<75% adhered (less than half the TDS lifting off skin); \< 50% adhered but did not detach (not detached, but more than half of the TDS lifting off skin without falling off); patch completely detached (TDS detached, completely off skin).

    Time frame: Twice daily during 36-day confinement period

07

Study locations

1 site
  • Celerion
    Phoenix, Arizona 85283, United States
08

References and documents

Individual participant data

Plan to share: No — No Plans

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Jul 2017, 8 months.

Of 161 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's 8 months is below that.

Counting every sponsor, half of 234 studies reached it within 17 months; a quarter within 7 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2016
First posted
Nov 21, 2016
StartActual
Nov 2016
Primary completionActual
Jul 11, 2017
CompletionActual
Jul 11, 2017
Last update
Aug 1, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02968719
Lead sponsor
Corium, Inc.
Responsible party
Sponsor
First posted
Nov 21, 2016
Start date
Nov 2016
Primary completion
Jul 11, 2017
Completion
Jul 11, 2017
Last update
Aug 1, 2018

Study contacts

Danielle Armas, MD
principal investigator · Celerion

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donepezil

Start the discussion